|
GMEB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.49640000000207E-05 |
| Normal-vs-Stage3 |
3.23074900165921E-14 |
| Normal-vs-Stage4 |
3.06754621703931E-12 |
| Stage1-vs-Stage2 |
5.208100E-02 |
| Stage1-vs-Stage3 |
4.259800E-01 |
| Stage1-vs-Stage4 |
5.415800E-02 |
| Stage2-vs-Stage3 |
1.489910E-02 |
| Stage2-vs-Stage4 |
5.156900E-03 |
| Stage3-vs-Stage4 |
2.537600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.94590000000195E-05 |
| Normal-vs-Asian |
3.63864494090649E-12 |
| Caucasian-vs-AfricanAmerican |
3.271000E-01 |
| Caucasian-vs-Asian |
7.260600E-01 |
| AfricanAmerican-vs-Asian |
5.362400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.17430518034689E-11 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
5.209000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
7.70494779089859E-13 |
| Normal-vs-Age(61-80Yrs) |
2.02170502561216E-11 |
| Normal-vs-Age(81-100Yrs) |
3.036000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.645400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.374600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.224200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.130800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.264600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.795800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.59395999999035E-05 |
| Classical-VS-Follicular |
2.658100E-02 |
| Classical-VS-Other |
4.058400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
2.37670000013956E-07 |
| Tall-VS-Other |
2.199200E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.868450E-01 |
| Follicular-VS-Normal |
3.12309999994653E-06 |
| Other-VS-Normal |
8.41670000000239E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.77513559407316E-12 |
| Normal-vs-N1 |
9.88098491916389E-15 |
| N0-vs-N1 |
7.202800E-03 |
|
|
